Jeffrey L. Ambroso is a board-certified toxicologist with 21 years of experience in nonclinical safety evaluation of drugs and biotechnology products, in both public and private sectors. At RTI International, Jeffrey works closely with both the TB Alliance and CARB-X to develop novel therapies to treat bacterial pathogens. He has served as the preclinical safety representative on multiple project teams developing drugs for a variety of indications.

Antoine Andremont is currently Emeritus Professor at the Paris Diderot University Medical School, France, a scientific advisor at the French Ministry of Higher Education, Research and Innovation, and serves as an expert witness for the French National Highest Judiciary Court (Cour de Cassation). He is also the co-founder and a senior scientific advisor at biotechnology company Da Volterra - which he created in 2000 to research and understand the impact of antibiotics on the intestinal flora microbiota, the development and

John van den Anker is a renowned paediatric consultant based at the Children’s National Medical Center Washington, DC, whose research has resulted in a much more evidence-based use of antibacterial agents such as aminoglycosides, cephalosporins, penicillins, meropenem, and vancomycin in children. John holds many titles including, the Evan and Cindy Jones Endowed Professor of Paediatric Clinical Pharmacology at Children’s National Medical Center; the Eckenstein-Geigy Distinguished Professor in Paediatric Pharmacology and Pharmacometrics at the University of Basel Children’s Hospital in Switzerland,

Jesús Rodríguez-Baño is Professor of Medicine at the University of Seville and Head of the Infectious Diseases division at Hospital Universitario Virgen Macarena in Seville, Spain. He is also Scientific Chair of the Spanish Network for Research in Infectious Diseases (REIPI), which is funded by Instituto de Salud Carlos III, and President-Elect of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Jesús is a medical doctor and specialist in internal medicine, who gained his PhD in medicine in

Carl Balibar is a Principal Scientist in the department of Infectious Disease and Vaccines at Merck & Co. which he joined in 2012. He is an expert in antibiotic mechanism of action and antibacterial drug discovery. He is specifically responsible for efforts ranging from early discovery and target validation through clinical development utilizing various modalities in support of anti-infective drug discovery. Carl has written more than 30 papers and book chapters and participated in the discovery and development of the

Michael Barbachyn is the Brummel Chair and Professor of Organic Chemistry at Calvin College, Michigan, US, and an independent consultant at Barbachyn Consulting. Michael has over 27 years’ experience in medicinal chemistry as a research scientist following periods at Upjohn, Pharmacia & Upjohn, Bristol-Myers Squibb, Pharmacia, Pfizer and AstraZeneca, focused on anti-infectives. Michael also has 12 years’ pharmaceutical industry management experience as an associate director and director in antibacterial medicinal chemistry at Pharmacia and then Pfizer; and as an infection

Greg Basarab is Principal Research Officer and Associate Director at the University of Cape Town (UCT), Drug Discovery and Development Centre (H3D). He is Head of drug metabolism and pharmacokinetics (DMPK) and pharmacology groups located at Groote Schuur Hospital, Head of Institute of Infectious Diseases and Molecular Medicine, and Head of Medicinal Chemistry groups within the UCT Chemistry Department. He lectures at the UCT Medical School on Drug Disposition and Pharmacology. Greg worked in various aspects of antibacterial and antifungal

Alex van Belkum is currently Scientific Director of Microbiology Research at bioMérieux, a diagnostics company based in the South of France. He is also a fellow of the American Academy of Microbiology. Alex is a microbiologist in the data analytics unit of bioMérieux with a prime interest in next generation sequencing, and the use of other data-rich technologies in clinical microbiology. His long career has been dedicated to the research of molecular epidemiology, molecular and culture-based diagnostics and antimicrobial resistance

Peter Beyer is a trained lawyer and Senior Advisor at the World Health Organization (WHO) where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments. Peter was involved in establishing the Global Antibiotic R&D Partnership (GARDP) as a WHO and DNDi joint initiative as well as the trilateral collaboration among the World Intellectual Property Organization (WIPO), the World Trade

Julia Bielicki is currently a consultant in Paediatric Infectious Diseases and Infection Prevention and Control at the University of Basel Children’s Hospital. She is also an active researcher with the Paediatric Pharmacology Division at the University of Basel Children’s Hospital and a Senior Lecturer with the Paediatric Infectious Diseases Research Group at St George’s University of London. Furthermore, Julia is involved in developing a national antimicrobial stewardship programme in Switzerland. Julia’s research focuses on observational and interventional studies that aim

Helen Boucher is currently chief of the Division of Geographic Medicine and Infectious Diseases. She is also Director of the Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR), a collaborative, cross-disciplinary initiative between Tufts University and Tufts Medical Center. She is Director of TMC’s Heart Transplant and Ventricular Assist Device Infectious Diseases Program and Professor of Medicine at Tufts University School of Medicine. Her clinical interests include infections in immunocompromised patients and S. aureus infections, and her research focuses

Pamela Brown has over 30 years’ experience in anti-infective drug discovery gained within the biotech and pharmaceutical sectors. She is currently a consultant in Antibacterial Drug Discovery and Medicinal Chemistry offering independent advice and expertise to small and medium-sized enterprises (SMEs), biotechs and academic institutions. Pam was Director, Medicinal Chemistry at Cantab Anti-infectives for five years following its inception in 2012. There, Pam led the medicinal chemistry team towards novel polymyxins, resulting in a commercial deal with Spero Therapeutics in

Vincent Cattoir is currently Professor of Clinical Microbiology at the University of Rennes 1, and Head of the Clinical Bacteriology department of the University Hospital of Rennes, France. Vincent is the Director of the Lab Enterococci, affiliated to the National Reference Center for Antimicrobial Resistance. He is also a senior scientist in the INSERM U1230 at the University of Rennes 1, currently focused on regulatory mechanisms involved in the pathogenicity and antimicrobial resistance in opportunistic bacterial species such as Enterococcus

Ryan Cirz is an independent consultant. Previously, he was founder and vice President of Research at Achaogen. Achaogen focused on discovering, developing and commercializing innovative antibacterials to treat multi-drug resistant (MDR) Gram-negative infections. Here, he participated in and led the advancement of four home-grown antibacterial assets through investigational new drug applications. Three of those programs advanced into the clinic with two advancing past phase one studies and one through US approval in 2018. At Achaogen, he oversaw the early-stage (pre-investigational

Anthony Coates is the Founder and Chief Scientific Officer of Helperby Therapeutics, a biopharmaceutical company dedicated to developing the next generation of lifesaving antibiotics. Anthony created the company in 2002 and together with colleague Yanmin Hu invented Antibiotic Resistance Breakers (ARBs), a new form of ‘antibiotic renewable’ technology. With existing antibiotic treatments rapidly becoming obsolete, Helperby’s unique antibiotic technology outsmarts highly resistant bacteria by combining ARBs with old antibiotics such as colistin, to create a new and sustainable commercially viable

James (Jim) Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT), as well as a member of the Harvard-MIT Health Sciences & Technology Faculty. He is a core founding faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, and an Institute Member of the Broad Institute of MIT and Harvard. Being one of the founders of the field of synthetic biology, his research

Matthew Cooper is co-founder, Director and Chief Executive Officer of Inflazome, which develops inflammasome inhibitors for chronic inflammatory diseases. Matt is also Co-Founder and Director of Defensin Therapeutics and Affiliate Professor at Trinity College Dublin. He holds a fractional Professorial Research Fellow appointment at the University of Queensland, where he is Professor of Chemical Biology at the Institute of Molecular Bioscience and, Affiliate Professor in the School of Chemistry and Molecular Biology. Matt obtained his PhD in 1995 in organic

Lloyd Czaplewski is Chief Scientific Officer for Persica Pharmaceuticals Limited and a Director of Chemical Biology Ventures where he provides life and chemical sciences consultancy services. Previously, Lloyd has served as an R&D executive for Biota, Prolysis, and British Biotech Pharmaceuticals. In his scientific career so far, he has led the creation and clinical evaluation of an engineered cytokine, discovery of the potential for minimal lentiviral vectors in antigen presentation, and demonstrating ability to create and lead structure-informed screening. He

Mike Dawson is a consultant in antimicrobial research, who has spent the last 14 years working in the biotech sector. Mike also has over 20 years’ experience in the pharmaceutical industry gained at GSK. As Head of Biotransformation and Natural Product Chemistry he played leading roles in natural product based drug discovery and the application of biological processes to drug manufacturing. He left GSK in 2003 to set up Novacta Biosystems where, as Chief Scientific Officer (CEO), he led the

David Denning is an infectious diseases clinician with expertise in fungal diseases. He has been a Professor of Infectious Diseases and Global Health at the University of Manchester since 2005. From 2009 to 2020, David led the National Aspergillosis Centre, Manchester, a referral centre in the UK for all patients with chronic pulmonary aspergillosis. His current academic interests are chronic and allergic pulmonary fungal disease, the global burden of fungal infection, resistance in Aspergillus and getting new antifungals developed. He

Harpal Dhillon is a pharmacist, founder of AntiBx and a Global Medical Value consultant. Harpal has amassed over 15 years of experience working across healthcare, public health, academia and the pharmaceutical industry in a variety of roles within infectious diseases. He has specialized in developing innovative strategies and initiatives to optimize antibiotic prescribing. This has included the launch of TARGET antibiotics in the UK and the execution of an EU-wide compassionate use programme for an antibiotic. His experience led to

Jacques Dumas is a trained chemist with over 20 years’ experience in discovery to clinical proof-of-concept in infectious diseases and oncology. He has been Chief Scientific Officer (CSO) of Tetraphase Pharmaceuticals since July 2015, where he oversees non-clinical sciences and CMC (Chemistry, Manufacturing and Controls) activities to support the company’s product pipeline. Jacques became CSO at Idenix Pharmaceuticals in January 2014, then Vice President at Merck following Merck’s acquisition of Idenix. Between 2007 and 2014, Jacques held several positions at

Barry Eisenstein is the chair of the Scientific and Business Advisory Board of CARB-X, a public-private partnership based at Boston University, devoted to new antimicrobial drug and diagnostic development. Barry received his medical degree from Columbia University and subsequently trained in internal medicine and infectious diseases at the University of North Carolina. He has spent his career in academy and industry, serving as Chief of the Infectious Diseases division at the University of Texas Health Science Center, San Antonio then

Alice Erwin is an independent scientific consultant, providing advice on antibiotic discovery to academic and industrial research groups. She also conducts due-diligence evaluation of antibacterial programmes being evaluated as in-licensing or investing opportunities. Alice is an infectious disease microbiologist with experience in both academic and industrial settings. Her scientific research over the past thirty years has revolved around the structure and function of bacterial membranes, with particular interest in the contribution of lipopolysaccharides to both the pathogenesis and the intrinsic

Cecilia joined the Foundation for Innovative New Diagnostics (FIND) as AMR Medical Officer in 2018. Here, she supports projects addressing gaps in the availability and use of diagnostic tests for antimicrobial resistance in order to better guide the appropriate use of treatments. Prior to joining FIND, Cecilia worked at Médecins Sans Frontières (MSF) for 14 years in several countries such as China, Somalia, South Sudan and Uganda. In this role, she implemented HIV and tuberculosis (TB) activities in conflict affected

Lena Friberg is Professor of Pharmacometrics at the Faculty of Pharmacy at Uppsala University, Sweden, a position she has held since 2014. Lena obtained her PhD degree in Pharmacokinetics and Drug Therapy in 2003 and spent nearly two years as a postdoctoral fellow at the University of Queensland in Australia. She has published over 125 original articles and nearly 15 reviews and book chapters in the area and has an H-index over 40. Her research is focused on advancing pharmacometric

Domingo Gargallo-Viola is a co-founder and Chief Scientific Officer at ABAC Therapeutics, a leader in pathogen-specific antibiotics that was formerly part of Grupo Ferrer Internacional based in Spain. Domingo has over 30 years’ experience in the discovery and development of anti-infective drugs. At ABAC Therapeutics he is focused on the discovery and development of first-in-class, novel mechanism of action, pathogen-specific, narrow spectrum antibiotics - for the treatment of severe and life-threatening infections due to multidrug-resistant organisms. He is also responsible

Olga Genilloud, Scientific Director and Head of the Microbiology Department at Fundación MEDINA, has over 25 years’ extended research experience in the discovery and biosynthesis of novel natural products antibiotics, obtained in the academic, clinical environment and pharmaceutical sectors. Olga has a PhD in chemistry from the Complutense University of Madrid and has a solid background in industrial microbiology - with expertise in bacterial natural products, molecular biology, ecology and taxonomy, physiology, and production of secondary metabolites. Since 2009, Olga

Mark Goldberger is an independent consultant at Mark Goldberger MD MPH LLC Maryland, USA, where he advises pharmaceutical and biotech companies on the development of infectious diseases products. Before retiring in 2014 and becoming a consultant, Mark spent seven years at AbbVie - formerly part of Abbott - in various senior positons including vice president of regulatory affairs and senior advisor. In these roles he provided regulatory guidance and strategic advice with a focus on US Food and Drug Administration

Trudy Grossman is Vice President of Research at Azitra Inc., a company developing microbial-based therapies aimed at treating skin disorders. Previously she was Senior Director of Biology and Pharmacology at Melinta Therapeutics in New Haven, Connecticut, where she managed a team supporting antibiotic discovery and development. Trudy has worked in microbiology in increasing roles of seniority for over 25 years; most of that time applying the genetics, molecular biology, physiology, and biochemistry of bacteria to the discovery and development of

Bob Hancock is a leading microbiologist in Canada, who has researched and taught at the University of British Columbia (UBC) for nearly 40 years. Bob is currently UBC Killam Professor of Microbiology and Immunology, an Associate Faculty Member at the Wellcome Trust Sanger Institute in the UK, and a Canada Research Chair in Health and Genomics. Bob is focused on designing new therapeutic strategies to treat infections - in the light of increasing antibiotic resistance and a dearth of new

Stephen is Chief Executive Officer of IHMA Europe Sàrl based in Switzerland, a wholly owned affiliate of International Health Management Associates. Since it began operating in 2009, under Stephen’s leadership, IHMA has focused on providing a full suite of technical capabilities and domain expertise in all phases of antimicrobial drug development: drug discovery, clinical development, regulatory approval and commercialization. Before joining IHMA, Stephen held several key positions in the pharmaceutical industry spanning 15 years, focused on antibacterial and antifungal research

Paul Heath is a Professor and Honorary Consultant in Paediatric Infectious Diseases at St George's University Hospital’s NHS Foundation Trust and St George’s, University of London, where he co-leads the Paediatric Infectious Diseases Research Group and is the Director of the Vaccine Institute. Before joining St George’s, Paul was a research fellow in the Oxford Vaccine Group Department of Paediatrics, at John Radcliffe Hospital, Oxford. Paul’s research has focused on the epidemiology of vaccine-preventable diseases, and clinical vaccine trials, particularly

Paul J. Hergenrother is the Kenneth L. Rinehart Endowed Chair in Natural Products Chemistry at The University of Illinois at Urbana-Champaign. He established his own laboratory in 2001 which seeks to understand compound accumulation in Gram-negative bacteria to then use this information to create novel antibiotics. Paul is the co-founder and Chief Scientific Officer of Vanquish Oncology, and an anticancer compound discovered by his lab is now being used in multiple clinical trials. Paul has received numerous awards including the

Edward W. Hook III is an Emeritus Professor of Medicine at the University of Alabama at Birmingham (USA) with expertise in infectious diseases, microbiology and epidemiology. In his role as a clinical investigator with a focus on sexually transmitted infections, Edward has led and participated in clinical trials of new antimicrobials, vaccines, and diagnostic tests as well as conducting epidemiologic research on a variety of topics. He has consulted with the National Institutes of Health (NIH), the Centers for Disease

William Hope is the Dame Sally Davies Chair of AMR Research and Professor of Therapeutics and Infectious Diseases at the University of Liverpool where he also leads the Centre for Antimicrobial Pharmacodynamics (CAP). As part of the university’s Institute of Translational Medicine, this centre provides the pharmacodynamic packages for the development for new antimicrobial agents. William qualified in medicine in 1991, before undertaking specialist training in infectious diseases and clinical microbiology. He completed his PhD in antimicrobial pharmacology in 2006,

Diarmaid Hughes is Professor of Medical Molecular Bacteriology at Uppsala University, Sweden. He has been working actively within the Innovative Medicines Initiative (IMI), New Drugs for Bad Bugs (ND4BB), ENABLE Project since its beginning in February 2014. ENABLE is a public-private partnership involving collaboration between more than 40 partners including several European Federation of Pharmaceutical Industries and Associations (EFPIA) companies, multiple small and medium-sized enterprises, research institutes, academic hospitals and universities spread throughout Europe. ENABLE’s remit is to develop promising

Deborah Hung is is currently an associate professor in the Department of Molecular Biology at Massachusetts General Hospital and in the Department of Genetics at Harvard Medical School. She is Director of the Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, an infectious disease physician at Brigham and Women’s Hospital and Massachusetts General Hospital and is an attending critical care physician in the Medical Intensive Care Unit at Brigham and Women’s Hospital. Deborah works at the interface

Khalid Islam is the owner of Life Sciences Management GmbH, which consults with start-ups, emerging biotechs and pharma on drug discovery and development. He is also a founding partner of Sirius Healthcare Partners, an advisory boutique in the healthcare sector. Khalid is the Chairman of the Board of Directors of Fennec Pharma and Minoryx Therapeutics, a member of the Board of Directors of Immunomedics and an advisor to the Paris-based venture group Kurma Biofund. Khalid has over 30 years’ experience in

Nachum Kaplan is a co-founder of Nobelex Biotech and has been the Chief Scientific Officer (CSO) since its inception in 2014. Nachum leads on the discovery of new drugs, including overseeing antibacterial compound progression relative to milestone criteria and target product profiles. Nachum is also responsible for all in vitro microbiology studies, in vivo efficacy models and pharmacokinetic/pharmacodynamics (PK/PD) modelling. Before creating Nobelex, Nachum was CSO of Affinium Pharmaceuticals, a drug discovery and development company focused on novel antibiotic therapeutics.

Anders Karlén is a professor of Computer-Aided Drug Design at Uppsala University and focuses on hit identification and lead development in antibacterial drug discovery. His research group studies targets of importance in infectious diseases with a focus on tuberculosis and Gram-negative infections. At Uppsala University, he is the overall medicinal chemistry project leader for drug discovery efforts directed at several different anti-bacterial targets. Since February 2014, Anders has led the Managing Entity as well as been co-coordinator of the project

Cassandra Kelly-Cirino is Director of Emerging Threats at the Foundation for Innovative New Diagnostics (FIND). She joined this organization in 2017 with over 20 years of experience working in Canadian and US public health and private sector settings. Most recently, Cassandra was responsible for multiple initiatives to bring simple collection and stabilization solutions to the global public health and outbreak response fields at DNA Genotek. She has supported the development of public health policy for infectious diseases with a focus

Kevin Krause is Vice President of Clinical Sciences and Development at AN2 Therapeutics, a company he joined in November 2019. Here, he focuses on the development of treatments for infectious diseases with a high unmet need. Before joining AN2 Therapeutics, Kevin was part of the senior leadership team at Achaogen. During his time there, Kevin led plazomicin out-licensing efforts for key regions. He also played an instrumental role in the phase 3 development programme, regulatory defense and launch of this

Sushmita Lahiri is Associate Director and a member of the External Innovation, Research Beyond Borders team at Boehringer Ingelheim. This group is the company’s radar for the next wave of innovation and is responsible for identifying emerging science and technologies in Gene therapy, Regenerative medicine, Microbiomes and Infectious diseases. Sushmita is responsible for establishing and leading research collaborations in infectious diseases in partnership with academia and small biotech companies. Prior to this role, Sushmita was Executive Director of Biology at

Ramanan Laxminarayan is founder and director of the Center for Disease Dynamics, Economics & Policy (CDDEP) and a senior research scholar at Princeton University. He is an affiliate professor at the University of Washington and a visiting professor at the University of Strathclyde in Scotland as well as the University of Kwazulu Natal in South Africa. He also chairs the boards of GARDP and HealthCubed. Since 1995, Ramanan has worked to improve the understanding of antibiotic resistance as a problem

Jennifer Leeds is Executive Director and Head of West Coast Search and Evaluation, Business Development and Licensing, for the Novartis Institutes for Biomedical Research (NIBR). She is responsible for identifying new science and technology from the western United States for potential partnering with Novartis. Before assuming her current role, Jennifer Leeds was Head of Antibacterial Discovery in the infectious diseases area of NIBR. She was responsible for the strategy and execution of the new antibacterial portfolio from target discovery through

Alexander Lepak is an Assistant Professor at the University of Wisconsin in the Department of Medicine, Division of Infectious Diseases. He is an active physician, educator and researcher. Alexander directs antimicrobial stewardship quality improvement initiatives and research projects. His main research pursuits are in performing and translating antimicrobial pharmacodynamic (PD) studies (both in vivo animal models and patient-level data) to optimize therapy against numerous pathogens. This research has specifically included medically important fungal and bacterial pathogens, including those that are

David Lewis is currently the Director of Western Sydney Sexual Health Centre and conjoint Professor at the University of Sydney, Australia. Throughout his career, David has had a special interest in the clinical, microbiological and public health aspects of sexually transmitted infections (STIs) and HIV. David graduated as a medical doctor from the London Hospital Medical College, London University in 1987. Following senior house officer positions in general medicine, haematological oncology, infectious diseases, genitourinary and HIV medicine, David underwent specialist

Jian Li is Head of the Antimicrobial Systems Pharmacology Laboratory at the Biomedicine Discovery Institute, Monash University in Melbourne, Australia. He has also been a Web of Science Highly Cited Researcher in Pharmacology and Toxicology (2015-2017). Jian has an internationally leading track record in the pharmacology of polymyxins and the discovery of new antibiotics against Gram-negative ‘superbugs’. The majority of modern polymyxin pharmacology data were reported by his research group and he is the Editor-in-Chief of the first-ever book on

Troy Lister is Vice President of Research and Development at Spero Therapeutics in Cambridge, Massachusetts. Before joining Spero Therapeutics in 2014, Troy was previously team leader of infection chemistry at AstraZeneca and Investigator III in Global Discovery Chemistry at the Novartis Institute for BioMedical Research (NIBR). He has led numerous discovery programmes searching for novel agents to target bacterial and viral pathogens including both Gram-negative and Gram-positive multidrug-resistant bacteria as well as other pathogens such as respiratory syncytial virus and

Sergio Lociuro is Chief Scientific Officer (CSO) at BioVersys AG where he leads the research and development of novel chemical entities that, upon binding to bacterial transcription regulators, are able to control/inhibit expression of resistance to given antibiotic classes, biofilm formation and virulence factors. Sergio has over 30 years’ experience in applied sciences and drug discovery gained in academia and pharma. He has held several positions in small and large pharmaceutical companies, such as a scientific coordinator at MMD (Lepetit),

Alexander Mankin is Distinguished Professor and Director of the Center for Biomolecular Sciences at the University of Illinois at Chicago (UIC), USA. He also holds the title of A. Neyfakh Collegiate Professor at the College of Pharmacy, UIC. Alexander’s research focuses on the mechanisms of action of ribosomal antibiotics. Through research carried out by his laboratory and collaborations with pharmaceutical companies, he has helped identify the sites and modes of action of several important classes of antibacterials, including oxazolidinones, ketolides,

Jeanne Marrazzo is Professor of Medicine and Director of the Division of Infectious Diseases at the University of Alabama, Birmingham, USA. She is internationally recognized for her research and education efforts in the field of sexually transmitted infections (STIs), especially as they affect women’s health. She is a fellow of the American College of Physicians and of the Infectious Diseases Society of America. She is board certified in infectious diseases. Jeanne conducts research on the human microbiome, specifically as it

Marc Mendelson is a Professor and Head of the Division of Infectious Diseases and HIV Medicine at Groote Schuur Hospital, University of Cape Town. He is Chair of the South African Ministerial Advisory Committee on AMR and co-founder of the South African Antibiotic Stewardship Programme. His interests lie within national and international policy development on AMR as well as building antibiotic stewardship models in low-resource settings. Marc works with the World Health Organization (WHO) on several of its AMR technical

Alita Miller is a Vice President of Biology at Entasis Therapeutics, a small biotech outside of Boston, USA, dedicated to the discovery and development of novel antibacterial agents to treat serious infections by resistant Gram-negative bacteria. At Entasis, Alita oversees both preclinical biology and developmental microbiology research. As a member of the senior leadership team, she is also involved in the strategic planning and execution of the company’s long-term research objectives. Alita has over 18 years’ experience in antibacterial research,

Stefan Miller is a scientific consultant at Lysando AG and an independent consultant. He has significant experience as a chief scientific officer (CSO) and chief executive officer (CEO) in biotech companies and focuses on technology and product development including intellectual property strategy. Stefan co-founded Profos AG in 2000 and was its CSO until 2008. There he led the development of microbial diagnostics products and worked on bacteriophage endolysins as novel targeted antibacterials for Gram-positive bacteria. To overcome the limitations of

Michael Mourez is Head of the Bacteriomics platform at Evotec in Lyon, France. He previously worked at Sanofi on their discovery platform in the therapeutic area of infectious diseases and then at Evotec once Sanofi transferred this portfolio. Michael is now located in Lyon, where he oversees technology platforms addressing severe bacterial infections, especially drug resistance. Michael received a Canada Research Chair Award for his work on bacterial animal diseases as well as numerous grants and awards. Michael trained in

Alex O’Neill is Associate Professor at the University of Leeds, UK, and heads a research group whose aim is to better understand and address the problems presented by antibiotic resistance in bacterial pathogens. Alex’s twenty-year academic career has involved two particular areas of focus. The first is concerned with elucidation of the molecular mechanisms by which bacteria resist the effects of antibiotics. The second – and the one of greatest relevance to REVIVE – involves the discovery and biological characterization